智通财经APP讯，中国同辐(01763)公布，近日，中国同辐附属公司成都中核高通同位素股份有限公司(中核高通)正式发布了基于第四代“MOF”材料的同位素分离新技术——“吸附捕手”，为高端核医疗和可控核聚变领域注入新动能，开辟了产业化发展新前景。
“吸附捕手”技术创新性引入了2025年诺贝尔化学奖聚焦的第四代“MOF”材料，突破传统同位素分离技术的固有框架，在分子尺度上实现分离材料的“定制化设计”。“吸附捕手”技术展现出“高纯度、高效率、低成本、低能耗”的显著优势，应用面广泛，覆盖核医疗、核聚变、重水堆、生物医学研究等多个面向国民经济主战场的关键领域，将为我国构建“自主可控、安全稳定”的同位素供应链提供核心科技支撑，助力打破部分高端同位素依赖进口的局面。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.